摘要
目的 分析替吉奥联合伊立替康治疗晚期胃癌的疗效。方法 选择符合研究要求的80例晚期胃癌患者作为研究案例,随机分为甲组和乙组,分别实施的是奥沙利铂联合5-氟尿嘧啶/亚叶酸钙方案以及替吉奥联合伊立替康治疗,治疗后对结果分析。结果 乙组和甲组的控制率分别是87.5%和62.5%,乙组和甲组不良反应率分别是5%和15%。两组比较,差异有统计学意义(P<0.05)。结论 晚期胃癌患者实施替吉奥联合伊立替康治疗,符合具体治疗要求,能减少患者自身不良炎症,值得实施和推广。
Objective To analyze the efficacy of Tegafur combined with irinotecan in the treatment of advanced gastric cancer. Methods 80 patients with advanced gastric cancer who met the study requirements were randomly divided into group A and group B.Oxaliplatin combined with 5-fluorouracil/calcium folinate and Tegafur combined with irinotecan were used to treat the patients.The results were analyzed after treatment. Results The control rates of group B and group A were 87.5% and 62.5%,respectively.The adverse reaction rates of the two groups were 5% and 15% respectively. Conclusion Tegafur combined with irinotecan in the treatment of advanced gastric cancer meets the specific requirements and can reduce patients adverse inflammation,which is worthy of implementation and promotion.
作者
张春雨
ZHANG Yuchun(Three Departments of Internal Medicine,Yichun First Hospital,Yichun,Heilongjiang Province,153000,China)
出处
《吉林医药学院学报》
2019年第5期334-335,共2页
Journal of Jilin Medical University
关键词
替吉奥
伊立替康
晚期胃癌
疗效
Tegafur
irinotecan
advanced gastric cancer
efficacy
